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1. Introduction
The literature is replete with evidence of a new complication associated with the use of bi‐
sphosphonates defined as avascular osteonecrosis of the jaw. This chapter discusses this is‐
sue and its diagnosis and management.
2. Background
According to Danneman et al. [1], all cases of osteonecrosis of the jaw described until 2006 were
associated with the use of the amino-group containing bisphosphonates only. Isolated reports of
osteonecrosis of the jaw caused by prolonged oral administration of alendronate (Fosamax) for
established osteoporosis can be found in the literature, including our previous publication. [2]
Most published cases were caused by intravenous administration of a bisphosphonate. Sook-
Bin Woo et al. reported that 94% of patients were treated with intravenous pamidronate or zole‐
dronic acid, and 6% received oral bisphosphonates for oseoporosis or for Paget's disease. [3]
Marx in 2003 was the first to report 36 cases of "painful bone exposure of the lower and up‐
per jaw in patients treated with bisphosphonates pamidronate and zoledronate". [4] That
same year, Migliorati reported five cases [5], Carter and Gross reported four [6] and Wang
reported three patients with this condition[7]. In 2004, Ruggierro et al. published 63 cases of
osteonecrosis of jaw bones in patients treated with bisphosphonates. [8] In 2005, Novartis
(the manufacturer of Aredia and Zometa) officially announced 475 cases of bisphosphonate–
related osteonecrosis of the jaw (BRONJ). [1] To date, numerous authors have reported cases
of osteonecrosis of the jaw bones associated with the use of bisphosphonates (Table 1). [9 –
15] The global number of cases of osteonecrosis of the jaw is unknown.
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Authors Number
of cases
Disease treated with
bisphosphonates
Kind of bisphosphonate Time period from
start of
bisphosphonate
therapy to
appearance of
BRONJ
Site of BRONJ
Marx [16] 119 Multiple myeloma – 62
Lung cancer with bone
metastasis – 50
Prostate cancer with
bone metastasis – 4
Osteoporosis - 3
Pamidronate – 32
Zolendronate – 48
Pamidronate и Zolendronate – 36
Alendronate - 3
14,3 months for
Pamidronate
9,4 months for
Zolendronate
12,1 months for
Pamidronate и
Zolendronate
3 years for
Alendronate
-
Ruggiero[8] 63
(18 males
and 45
females)
Multiple myeloma – 29
Lung cancer with bone
metastasis – 21
Prostate cancer with
bone metastasis – 3
Kidney cancer with
bone metastasis – 1
Leiomyosarcoma – 1
Leukemia - 1
Osteoporosis - 7
Pamidronate – 34
Zolendronate – 9
Pamidronate и Zolendronate – 13
Alendronate – 5
Risedronate – 1
Alendronate и Zolendronate - 1
- Mandible – 39
Maxilla – 23
Mandible plus
maxilla – 1
Dannemann[1] 14
(8 males
and 6
females)
Multiple myeloma – 7
Lung cancer with bone
metastasis – 6
Prostate cancer with
bone metastasis – 1
Zolendronate – 8
Zolendronate и Aredia - 6
Avg. 38,7 months
from the
beginning of
bisphosphonate
medication
(12 – 71 months)
Mandible – 9
Maxilla – 2
Mandible plus
maxilla – 3
Mavrokokki [17] 158 Multiple myeloma – 31
Bone metastasis – 51
Puget’s disease – 6
Osteoporosis - 26
Pamidronate – 20
Zolendronate – 43
Pamidronate и Zolendronate – 13
Alendronate – 30
Risedronate – 2
Clodronate – 2
Alendronate и Risedronate – 2
Alendronate и Pamidronate – 1
Zolendronate и Ibandronate - 1
26 doses of 62 mg
Zolendronate
19 doses of 9060
mg Alendronate
14 doses of 3285
mg Pamidronate
Mandible – 57
Maxilla – 24
Mandible plus
maxilla - 8
Table 1. Several case-series of BRONJ in the literature.
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3. Definition of BRONJ
Bisphosphonate–related osteonecrosis of the jaw is necrosis of the jaw bone, related or unre‐
lated to dental procedures, persisting for more than 6 to 8 weeks, refractory to conservative
treatment, in patients having no history of prior radiotherapy in the affected area, treated
intravenously with amino-containing bisphosphonates for at least one year, or orally for a
much longer period, for a general disease causing bone resorption.
4. Bisphosphonates
Bisphosphonates are a class of drugs influencing bone metabolism discovered in the late
1960's. They are used to treat diseases that feature high bone resorption (multiple myeloma,
osteolytic bone metastases, Paget's disease of bone [1], fibrous dysplasia [18, 19, 20],
McCune-Albright syndrome [21], hypocalcaemia of malignancy) and are most commonly
administered by intravenous infusion.
4.1. Mechanism of action
Bisphosphonates are synthetic analogues of inorganic pyrophosphates, which exert a potent
inhibitory effect on osteoclast activity. They feature slow intestinal absorption; they are ex‐
creted by the kidneys without metabolic alteration and have high affinity to hydroxyapatite
crystals. [22, 23] They incorporate into skeletal bones without being degraded. [24] Bi‐
sphosphonates attach to Ca2+ in areas of high bone resorption and remain integrated into the
bone for more than 10 years [25] ; for example, half-life of Alendronate is 12 years [24]. They
incorporate partially by pino- or phagocytosis into osteoclasts, osteoclast precursors, and al‐
so into macrophages, osteoblasts and chondroblasts. [26] Once taken, they trigger a cascade
of biochemical processes leading to loss of the ability of osteoclasts to resorb bone, or even to
their apoptosis. [27, 28]
4.2. Types of bisphosphonates
Bisphosphonates are classified based on their chemical structure (Table 2) [16, 29]
Aminobisphosphonates contain nitrogen in the side atomic chain of their molecule, with
a much stronger effect. Newer aminobisphosphonates have two actions; they induce oth‐
er  adenosine  triphosphate-analogues  that  cause  apoptosis;  and  they  inhibit  farnesyl  di‐
phosphate synthetase, which is part of the pathological cycle of cholesterol synthesis. [30]
Thus,  osteoclast  function  is  inhibited.  Some authors  suggest  that  aminobisphosphonates
reduce recruitment of osteoclasts,  and induce the production of osteoclast-inhibiting fac‐
tors by osteoblasts. [31, 32] The chemical structure of an aminobisphosphonate is shown
below [33]:
Bisphosphonate-Related Osteonecrosis of the Jaws – Diagnosis and Management
http://dx.doi.org/10.5772/53858
281
NH2
І
СН2
І
СН2
І
О СН2 О
ІІ І ІІ
ОН – Р – С – Р – ОNa . 3Н2О
І І І
ОН ОН ОН
Generic name Trade name Administration Type
Zoledronate ZometaAclasta IV aminobisphosphonate
Pamidronate ArediaPamiton IV/ Oral aminobisphosphonate
Alendronate FosamaxFosamax plus D3 Lindron
Oral aminobisphosphonate
Ibadronate BonivaBondronate IV/ Oral aminobisphosphonate
Risedronate ActonelActonel with Calcium Oral aminobisphosphonate
Tiludronate Skelid Oral non-aminobisphosphonate
Etidronate Didronel Oral non-aminobisphosphonate
Clodronate
Bonefos
Ostac
Sindronat
Clodron
IV/ Oral non-aminobisphosphonate
Table 2. Types of bisphosphonates.
Non-aminobisphosphonates - metabolized by osteoclasts to inactivate non-hydroxylysine
adenosine triphosphate-analogues that have a direct cytotoxic effect and lead to apoptosis.
[3] The chemical structure is shown below [33]:
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Until recently, bisphosphonates were administered predominantly as an intravenous infu‐
sion. Now, bisphosphonates in the form of tablets for oral administration are recommended
for patients with osteoporosis. The management strategy for osteoporosis is to prevent os‐
teoclast-mediated resorption of trabecular bone, and thus, maintain its density.
4.3. Bisphosphonate use
More than 2.5 million patients worldwide have been treated with bisphosphonates. [34] Al‐
most 2 million people receive treatment with bisphosphonates as part of their anticancer
therapy. [1] The number of patients treated with oral bisphosphonates for osteoporosis has
also been growing. In 2003 Alendronate was the 19th most commonly prescribed drug in the
world (17 million prescriptions), Risedronate was the 72nd with 6 million prescriptions, and
Zolendronate was taken by over 300,000 patients. [35, 36]
4.5. Adverse effects
Bisphosphonate therapy can lead to some adverse effects i.e. kidney failure [37], arthralgia,
fever, muscle pain and [38] hypocalcaemia [39]. In vitro and in vivo tests reported antiangio‐
genic (hence antitumour) effect of Zoledronic acid by inhibiting endothelial cell proliferation
and induction of apoptosis. [23, 40]
4.6. Possible mechanism leading to BRONJ
BRONJ probably results from suppression of bone metabolism established after bisphospho‐
nate treatment and from accumulation of physiologic microtraumas to the jaw bones, com‐
promising biomechanical properties. Trauma and infection increase the need for bone
recovery, which exceeds the capacity of hypodynamic bone, thus resulting in localized bone
necrosis. Antiangiogenic properties of bisphosphonates and other medications taken by pa‐
tients, and the presence of other comorbid factors may promote the risk of development,
persistence or progression of this condition. [3]
5. BRONJ
Sook-Bin Woo et al. assume that bisphosphonate-associated osteonecrosis develops only in
the jaw bones because they, unlike other bones in the body, are not sufficiently protected.
On one hand, an important fact is that they are protected from possible intraoral trauma on‐
ly by thin mucosa and periosteum. On the other hand, the presence of teeth in the jaw bone
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is a prerequisite which facilitates penetration of microorganisms and development of intra‐
osseous infections via deep caries complications and the periodontium. [3] In fact, one case
of bisphosphonate-associated osteonecrosis of the auditory canal in a patient treated with
Zoledronic acid in relation to multiple myeloma, published by Polizzotto et al. can be found
in literature; the lesion appeared after removal of exostoses in the external auditory canal,
but even in this case the patient had a concurrent osteonecrosis of the maxilla. [41]
5.1. Incidence of BRONJ
Reports on the incidence of the disease are variable. Most authors present statistical studies
of patients with multiple myeloma and lung cancer; the largest groups treated with bi‐
sphosphonates was a study of 1203 cases, of which 904 patients with multiple myeloma and
299 with lung cancer. Development of osteonecrosis of the jaw bones was found in 7% and
4%, respectively. [3] Bamias et al. studied 252 patients receiving intravenous bisphosphonate
therapy; 10% of patients with multiple myeloma and 3% of patients with lung cancer devel‐
oped osteonecrosis of the jaw bones. [39] Estilo et al. studied 124 patients with multiple
myeloma and lung cancer treated with intravenous bisphosphonates and found that osteo‐
necrosis of the jaw bones developed in 4 patients with myeloma and in 9 patients with lung
cancer. [42] Bilezian stated that the incidence of BRONJ is 1.3%. [33]
5.2. Clinical presentation
Clinically intraoral lesions in BRONJ look like zones of yellow-white hard bone, with soft or
indurated borders (Figs. 1-3).
Figure 1. BRONJ of the mandible.
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Figure 2. BRONJ of the maxilla.
Figure 3. Multiple lesions of the mandible
Extra-or intraoral fistulas may be found. Painful lesions may develop in the soft tissues; they
may conflux with the exposed bone and may involve large regions of the mouth. Some cases
of pathological fracture of the mandible as the first manifestation of the disease have been
described. [40] Danneman et al. suggest that unlike osteoradionecrosis, osteonecrosis of the
jaw has no preference for the mandible and it affects both mandible and maxilla. [1] Sook-
Bin Woo et al. in an overview of 368 cases, reported involvement of the mandible in 65% of
the cases, the maxilla in 26% and in both jaws in 9%. The ratio of women to men was 3:2.
The same author reported that most of the lesions were in the posterior regions of the man‐
dible, near the mylohyoid ridge. According to him, multifocal/ bilateral lesions were slightly
more frequent in the maxilla (31% compared to the mandible which was 23%). [3]
5.3. Paraclinical tests
In the early stages of the disease there may be no radiological changes. [3] Some authors rec‐
ommend performing computed tomography. [33] Chiandussi et al. suggest that later
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changes in jaw bones in bisphosphonate-associated osteonecrosis can be visualized by radi‐
ography, and for early detection of lesions it is necessary to perform computed tomography
examination or MRI. [43] Dunstan et al. recommend jaw bone scintigraphy with Tc-99m
methylene diphosphonate. [44] In advanced cases, the bone shows a moth-eaten appearance
[41] clearly identifiable radiologically with or without X-ray positive sequestra. Danneman
et al. argue that the sequestra typical of chronic osteomyelitis are not found in BRONJ. [45]
Microbiological testing most commonly finds actinomycete druses. [1, 46]
Histopathological analysis shows presence of necrotic bone surrounded by bacteria that do
not enter into it. [40] Three main histological patterns have been identified in BRONJ pa‐
tients [47] (Fig. 4):
1. Areas with active acute inflammation, characterized by predominance of soft tissues,
inflammatory infiltrate, acellular necrotic debris, thin-walled and dilated blood vessels,
and intensely basophilic bone spiculae with scalloped borders showing prominent bone
resorption.
2. Areas characterized by predominance of bony structures showing wide acellular ne‐
crotic sequestra and large, scalloped Haversian canals containing inflammatory cells.
3. Non-necrotic areas containing larger amounts of bone, showing increased trabecular
thickness, inter-osteonic bone deposition and smaller and fewer Haversian canals. Also,
lamellar bone from treated patients was composed of bigger osteones containing larger
osteocytes. Two different types of newly-formed woven bone, mainly showing centrifu‐
gal spatial orientation, were easily detectable in these areas. Osteoclast-like cells detect‐
ed in inflammatory areas from treated patients were small and contained few nuclei,
but they were rare to absent in non-necrotic bone from the same patients.
Figure 4. Microscopic view of necrotic bone in BRONJ.
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Figure 5. Another microscopic view of necrotic bone in BRONJ
6. Differential diagnosis
Differential diagnosis of ONJ includes [48]:
• Malignancies - differentiation is through histopathological analysis;
• Osteoradionecrosis if jaws were exposed to prior radiation;
• Osteomyelitis in which, unlike bisphosphonate-associated osteonecrosis, necrotic bone is
surrounded by vital bone, which reacts with a violent inflammatory reaction, thus limit‐
ing necrosis;
• Osteopetrosis - an extremely rare congenital condition;
• Bone necrosis in HIV-positive patients.
7. Risk factors for development of BRONJ
Mainly two groups of factors responsible for the development of jaw necrosis may be found
in literature – the first one investigates the bisphosphonate administered (type, regimen and
period of treatment), and the other one investigates the dental diseases and procedures that
are likely to mediate the onset of the condition.
7.1. Risk factors associated with bisphosphonates
• Kind of bisphosphonate that induces BRONJ more often
According Danneman et al., all cases of osteonecrosis of the jaw described until 2006 were
associated with the use of the amino-group containing bisphosphonates only. In literature
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there is no consensus on the question which amino-bisphosphonates cause more frequent
development of BRONJ (Table 3), but scientific evidence supports the predominant view
that the use of Zoledronic acid is the most risky. [39, 45, 49, 50]
Dannemann et al.
[45] Badros et al. [51] Clarke et al. [52] Durie et al. [50]
Total number of patients undergoing
bisphosphonate treatment 90 497 1203
Number of cases with BRONJ 23 22 25 75
Number of patients that received
Zolendronate 14 2 5 21
Number of patients that received
Pamidronate and Zolendronate 5 17 8 -
Number of patients that received
Pamidronate 1 3 10 17
Number of patients that received
Alendronate 3 - 2 -
Table 3. Development of BRONJ in patients receiving different types of bisphosphonates.
• Regimen
A safer regimen for bisphosphonate treatment in terms of developing BRONJ
Corso et al. published a study of multiple myeloma patients, divided into two groups; the
first group received bisphosphonate treatment under the standard regimen, i.e. monthly;
while the patients in the second group received bisphosphonates monthly in the first year,
and then at every third month. They found, with statistical reliability, fewer cases of BRONJ
in patients from the second group, while in the first group they found cases of jaw necrosis
after the first year of the initiation of treatment. The authors reported that the Skeletal-Relat‐
ed Events (SRE) index, which takes into account the condition of the bone system as a
whole, was comparable in both groups. [49]
• Duration of treatment
Relationship between the period of use of bisphosphonates and the risk of developing bronj
Bamias A et al. suggest there is a strong correlation between the duration of treatment with
bisphosphonates and manifestation of jaw necrosis; they found that the average period of
exposure to drugs in patients with BRONJ was 39.3 months (from 11 to 86 months) and in
patients without BRONJ was 19 months (from 4 to 84.7 months); and they defined the risk of
developing the condition to be from 1% at 12 months after the start of treatment to 11% in
the fourth year. The authors reported that these figures vary depending on the type of bi‐
sphosphonate administered ( in patients treated with Zoledronic acid only it was from 1% in
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the first year to 21% in the third year since initiating the treatment, while in patients treated
with Pamidronate with or without Zoledronic acid it was 0% in the first two years of treat‐
ment and up to only 7% after four years of treatment). [39] Corso A. et al. determined the
following periods for the development of BRONJ depending on the bisphosphonate admin‐
istered; in case of treatment with Pamidronate, necrosis was observed no earlier than 23
months after initiation of therapy; in case of administration of Zoledronic acid this period is
no shorter than 28 months; in concomitant use of Pamidronate and Zoledronic acid necrosis
can be observed no sooner than 43 months. [49] Badros et al. suggest that with each year
after diagnosing multiple myeloma and its treatment, the risk of developing BRONJ is in‐
creases by 57%. [4]
7.2. Risk factors related to the dento-alveolar system
• Anatomical comorbidity
This group of predisposing factors considers the presence of mandibular tori, palatal tori,
and bone exostoses as sites more easily subject to local traumatization during daily activi‐
ties. Marx et al. reported BRONJ in 9.2% on mandibular tori. [16]
• Diseases of dental hard tissues and supporting apparatus
Marx et al. found that the most frequent dental disorder concomitant with BRONJ is symp‐
tomatic or radiologically diagnosed periodontitis in 84% of patients. Caries in necrotic areas
was registered in 28.6%. [16]
• Dental procedures:
Literature is replete with the incidence of bisphosphonate-associated osteonecrosis of the
jaw associated with previous dental procedures compared to cases of the so-called sponta‐
neous BRONJ. [4, 18, 27, 28, 35, 39, 53] Woo Sook-Bin et al. [3] found that 33% - 86% of cases
of BRONJ reported in the literature occurred after different dental procedures (Table 4).
Marx [16] Dannemann [1] Bamias [39]
Total number of cases with BRONJ 119 23 17
Number of cases with BRONJ after tooth extraction 45 18 13
Number of cases with BRONJ after endodontic treatment 34 2
Number of cases with BRONJ after new or uncomfortable
denture 2
Number of cases with BRONJ after periodontal surgery 5 1
Number of cases with BRONJ after apecoectomia 1
Number of cases with BRONJ after dental implants 4
Table 4. Dental procedures as a risk factor to development of BRONJ
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7.3. Other risk factors
The literature discusses the role  of  therapy concomitant  with bisphosphonate treatment.
Immunosuppressive  effects  of  chemotherapy,  impaired  bone  remodelling  during  treat‐
ment  with  glucocorticoids,  antiangiogenesis  properties  of  Thalidomide  slow  down  the
reparative processes in the oral cavity,  and are a predisposing factors for the manifesta‐
tion of BRONJ. [54]
Each decade of age passed increases the risk of developing BRONJ by 9%. [4]
8. Where to refer the patient if BRONJ is suspected
If development of BRONJ is suspected, the patient should be referred to an oral or a maxillo‐
facial surgeon. Nastro et al. [55] emphasize the important role of these specialists and em‐
phasize that their intervention should not be underestimated. However, in all cases,
treatment should be conducted jointly with the specialist who prescribed the bisphospho‐
nates (the oncologist, haematologist, endocrinologist, etc.).
9. Termination of bisphosphonate therapy after diagnosis of BRONJ
There is no consensus on the need for discontinuation of bisphosphonate treatment after di‐
agnosing osteonecrosis of the jaw. Marx suggests that behaviour in terms of bisphosphonate
therapy in cancer patients shall be discussed with the oncologist on the purpose of deter‐
mining the benefit to risk ratio, in view of the long half-life (10 years) of bisphosphonates.
[16] Other authors share the same opinion. [48, 55] Dunstan et al. suggest that bisphospho‐
nate therapy be discontinued. [44]
10. Algorithm of actions following development of BRONJ
By summarizing the evidence found in literature, the following algorithm for treatment of
patients suspected to have BRONJ can be derived:
1. A careful clinical examination to find the location and volume of exposed necrotic bone
2. Imaging diagnostics of the affected jaw - X-rays, CT scans, MRI, bone scintigraphy
3. Providing material for histopathological analysis to exclude the presence of a systematic
process in the jaw (in case of multiple myeloma, a metastasis in case of oncological dis‐
eases or a primary neoplasm)
4. Providing material for microbiological examination with emphasis on fungal or other
pathological bacterial infections
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5. Treatment - It is assumed that BRONJ is an irreversible condition. [55, 56] Medical treat‐
ments are aimed at elimination or control of pain and at prevention of progression of
jawbone exposure. Necrotic bone itself is not painful - pain, cellulitis and cutaneous fis‐
tulas occur in case of secondary infection. Thus, a long-term and sometimes permanent
antibiotic treatment is recommended.
• Drug therapy - systematic medication treatment includes the triad:
• antibiotic
• antifungal agent
• antiviral agent
The first choice antibiotic is oral penicillin (Table 5).
Clinical condition Administer Antibiotic drugs and doses In cases of penicillin allergy
Slight Orally Penicillin(500 mg every 6 hours)
Ciprofloxacin
(500 mg every 12 hours)
or
Erythromycin ethylsuccinate
(400 mg every 8 hours)
Moderate Orally
Penicillin
(500 mg every 6 hours)
and
Metronidazole
(500 mg every 8 hours)
Ciprofloxacin
(500 mg every 12 hours)
or
Erythromycin ethylsuccinate
(400 mg every 8 hours)
and
Metronidazole
(500 mg every 8 hours)
Severe cellulitis IV
Unasyn
(1500 mg every 6 hours)
and
Metronidazole
(500 mg every 8 hours)
Table 5. Antibiotic treatment for control of diagnostic BRONJ by Marx et al. [16]
It is advisable that the therapy also include 0.12% chlorhexidine mouth rinse solution. [16]
Penicillin may be replaced with Dalacin C (600 mg at every 8 hours) or Doxycyclin (100 mg
every 12 hours for the first 24 hours, and 100 mg for every 24 hours after that). The Ameri‐
can Dental Association recommends the following oral antibiotics: Amoxicillin with or with‐
out Metronidazole, and in case of penicillin allergy Clindamycin or Azithromycin (Table 6).
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Drugs Doses Duration of treatment
AMOXICILLIN 500 mg every 8 hours 14 days
METRONIDAZOLE 250 mg every 8 hours 14 days
CLINDAMYCIN 300 mg every 8 hours 14 days
AZITROMYCIN 250 mg daily 10 days
Table 6. Antibiotics for oral use in BRONJ recommended by the American Dental Association [53]
Dunstan et al. [44] identified Penicillin, Clindamycin, Erythromycin, Nystatin, Fluconazole,
Acyclovir, Valocyclovir (for systemic use) and 0.12% chlorhexidine gluconate, minocycline
hydrochloride (mouth rinse) as typical drugs for treatment of osteonecrosis of the jaw. Marx
et al. suggest that the administration of Clindamycin only is not recommended because of its
ineffectiveness in terms of most frequently detected microorganisms in the exposed bones,
namely actinomycetes, Eikenella corrodens and other similar types. [16] Nastro et al. empha‐
size that antibiotics cannot penetrate into necrotic tissue, so they are used only for treatment
of cellulitis of the tissue adjacent to bone necrosis. [55]
• Surgery (debridement of the wound and covering it with an adjacent flap) - a method
of choice which most  authors do not  recommend [5,  8],  because of  the danger of  in‐
volving  new  bone  sections  in  the  process.  Marx  et  al.  [16]  reports  that  pathological
fractures in bisphosphonate-associated osteonecrosis of the jaw are extremely rare,  ex‐
cept in cases where debridement had been performed, thus weakening the bone. That
is  why he  recommends only  smoothening of  sharp bone edges  that  contribute  to  in‐
flammation  and  pain  in  the  affected  area.  Dunstan  et  al.  [44]  recommends  avoiding
surgery when the process starts, but argues that in some cases partial mandibulectomy
or maxillectomy is  required,  emphasizing the  idea of  sparing debridement.  Nastro  et
al.  [55]  also are not  supporters  of  surgery – they published a series of  12 cases,  only
one of  which was treated surgically,  and subsequently a  recurrence developed in the
same location of the jaw. Graziani et al. recommended performing sequestrectomy and
resection in certain cases but the treatment protocol to which they adhered to includ‐
ed primarily antibiotic  treatment,  combined with periodic debridement to remove ne‐
crotic  areas  aimed  at  reduction  of  symptoms.  [57]  In  the  literature,  there  is  an
underlying view that  aggressive  surgical  treatment  is  counterproductive  and leads  to
deterioration and therefore should be avoided. [5, 8, 16, 44]
• Hyperbaric oxygenation ( the evidence for its efficacy is controversial) application result
rather from the analogy with the treatment of osteoradionecrosis, in which stabilization of
the oxygen gradient is used. The mechanism of development of osteoradionecrosis and
BRONJ, however, is fundamentally different. [16] The prevailing opinion in the literature
is that hyperbaric oxygenation has no definite effect on the response of osteonecrosis of
the jaw, and its use is not recommended. [8, 44, 55, 56]
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• Ozone therapy, an experimental method of treatment, studied by Agrillo et al. [38], pub‐
lished a series of cases treated by the following regimen:
◦ Minimally invasive surgical curettage under local anaesthesia - the authors reported
the removal of necrotic bone in search of vascularized tissue, and limited deperiosteali‐
zation to mobilize the mucosal flap covering the bone wound;
◦ Medical treatment, including the antibiotic triad (amoxicillin with clavulanic acid, 1000
mg at every 12 hours) antifungal agents (250 mg at every 8 hours) and antiviral agents
(800 mg daily) for 20 days, and also vitamin C (3000 mg per day) for 20 to 30 days, local
antiphlogistic agents and 0.2% chlorhexidine mouth rinse.
◦ Ozone therapy with Ozonytron - pre-, intra-and postoperatively (2 applications, each
lasting for 5 minutes, per week, for 20 days) and repeating the course at the onset of
pain or a diagnosed infection.
Ozone has a positive effect on the bone defect by oxidation and stimulation and/or preserva‐
tion of endogenous antioxidant systems, and by blocking the xanthine/xanthine oxidase
pathological cycle. Ozone has a beneficial effect on blood circulation, it increases the number
of red blood cells and hemoglobin levels, accelerates diapedesis and phagocytosis and stim‐
ulates the reticulohistiocytic system. The described effects are most pronounced in small di‐
ameter vessels, such as the jaw vessels and capillaries. [9] Clavo et al. reported that ozone is
harmless to living tissue, and at certain concentrations it has analgesic effects. [58] Agrillo et
al. made the conclusion that ozone can be used in the treatment of patients with avascular
necrosis of the jaw due to its stimulating effects on the metabolism of oxygen, calcium, phos‐
phorus and iron. [38]
11. Prevention of BRONJ
At this stage there is no evidence-based therapeutic strategy for BRONJ and the condition is
considered to be irreversible, and therefore the attention of medical community focuses on
the possibilities of its prevention. [3, 53, 59, 60, 61, 62]
11.1. Before the start of bisphosphonate therapy
After establishing diagnosis requiring treatment with bisphosphonates, but before initiating
the therapy, the patient should be referred to a dentist and an oral or a maxillofacial sur‐
geon. The following plan for behaviour is recommended:
1. A thorough clinical examination of the dentition and oral cavity, panoramic radiograph
and, by the discretion of the doctor, targeted periapical radiographs as a mandatory re‐
quired minimum.
2. Conducting dental treatment aimed at elimination of infection and the need for invasive
procedures in the short- and mid-term future (Table 7).
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Procedure Interventions Antibiotic
prophylaxis
Standard drugs Drugs in cases of
penicillin allergy
Invasive dental
procedures
• Tooth extractions
• Periodontal surgery
• Endodontic treatment
• Excision of tori and
exostosis
• Extraction of impacted
teeth
Recommended Penicillin Ciprofloxacin
and
Metronidazole
or
Erythromycin
and
Metronidazole
Non-invasive
dental
procedures
• Prophylaxis
• Flouridization
• Filling caries
Not recommended
Table 7. Antibiotic prophylactic in cases of dental procedures preceding bisphosphonate treatment
It is appropriate that the specialized surgery in the oral cavity be in compliance with the fol‐
lowing recommendations:
• In terms of mandibular and palatal tori and exostoses, their removal is recommended on‐
ly in case of large and lobed structures covered with thin overlying mucosa.
• In terms of impacted teeth, surgical removal is recommended only for those which are not
fully covered by bone, communicating with the oral cavity, because of the danger of onset
of an inflammatory process in the future.
• Patients subject to bisphosphonate treatment are not eligible for restoration with dental
implants.
All invasive dental procedures should be performed at least one month before initiating bi‐
sphosphonate therapy in order to allow sufficient time for recovery of the jawbone.
11.2. After the start of bisphosphonate therapy
After the start of bisphosphonate therapy patients are subject to preventive check-ups at ev‐
ery four months, with radiographic examination, which should seek vigilantly for the pres‐
ence of osteolysis, osteosclerosis, and expansion of periodontium and involvement of
furcations. If additional treatment is required, non-invasive dental procedures are preferred.
Elective surgery does not lead to encouraging results. Placing dental crowns is permissible.
Removable dentures should be carefully planned in areas of expected excessive pressure,
giving preference to soft plastic structures. [16]
12. Conclusion
Bisphosphonate-associated osteonecrosis of the jaw bones is a newly discovered entity that
should be taken into account by dentists, hematologists, oncologists, endocrinologists and
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other medical professionals in their daily practice. At this stage, it is assumed that the condi‐
tion is irreversible. Therefore, efforts are focused on prevention and early diagnosis through
various paraclinical methods, if possible before clinical manifestation.This condition is sub‐
ject to further study. [63]
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